PAGANINI phase 2b data promising for eliapixant

Peter V. Dicpinigaitis, Rachel H. Giles
In: Medicom Conference Report ATS 2022 · 2022 · doi:10.55788/d266a780 · W4286462628
article OA: closed CC0
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
View at publisher → View on OpenAlex
⚙ AI-generated summary by claude@2026-07, 2026-07-29 ⓘ

Eliapixant, a P2X3 receptor antagonist, demonstrated promising efficacy and tolerability in a phase 2b study for patients with refractory chronic cough.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (1)

References (1)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK